文献速递脑血管病

缺血性卒中血管内治疗中围手术期静脉肝素的应用:MR CLEAN 登记研究结果

Periprocedural Intravenous Heparin During Endovascular Treatment for Ischemic Stroke: Results From the MR CLEAN Registry.
PubMed 文献 · Stroke · 2019-07-09

多水平回归分析显示,肝素使用与 90 天功能结局、成功再通、症状性颅内出血或死亡率均无显著差异(校正后 OR 见下),但中心层面分析显示肝素使用比例较高的中心功能结局更好(每增加 10% 的校正共同 OR 1.07,95% CI 1.01-1.13)。结论认为肝素使用存在中心间差异但安全,需随机试验进一步验证。

要点

  • 静脉肝素使用与 90 天功能结局无显著关联(校正共同 OR 1.17,95% CI 0.87-1.56)。
  • 肝素使用与成功再通、症状性颅内出血及死亡率均无显著差异。
  • 中心层面肝素使用比例越高,功能结局越好(每 10% 校正共同 OR 1.07,95% CI 1.01-1.13)。

核心结论

  • 围手术期静脉肝素的使用在中心间存在显著差异,但该治疗是安全的。
  • 中心层面肝素使用比例较高与更好的功能结局相关,但需随机试验进一步验证。

研究设计与样本

  • 采用多水平回归分析评估围手术期静脉肝素与结局的关联,并校正中心效应和预后因素。
  • 通过分析中心偏好(中心内肝素使用百分比)来应对可能的适应症混杂。

主要发现

  • 中心间肝素使用比例差异大(范围 0%-94%)。
  • 肝素组与非肝素组在 90 天功能结局(校正共同 OR 1.17,95% CI 0.87-1.56)、成功再通(校正 OR 1.24,95% CI 0.89-1.71)、症状性颅内出血(校正 OR 1.13,95% CI 0.65-1.99)和死亡率(校正 OR 0.95,95% CI 0.66-1.38)上均无显著差异。
  • 中心层面分析显示,肝素使用比例每增加 10%,功能结局更优(校正共同 OR 1.07,95% CI 1.01-1.13)。

关键数值与推荐

  • 主要结局为 90 天功能结局(改良 Rankin 量表)。
  • 次要结局包括成功再通(扩展脑梗死溶栓分级≥2B)、症状性颅内出血和 90 天死亡率。
  • 静脉肝素中位剂量为 5000 国际单位。

临床怎么用

  • 当前证据不支持围手术期常规静脉肝素的使用,但表明该治疗是安全的。
  • 中心层面肝素使用比例与更好结局相关,提示需随机试验进一步研究其疗效。

局限性

  • 研究为观察性登记分析,可能存在未测量的适应症混杂。
  • 中心偏好分析可能仍受中心层面混杂因素影响。
  • 肝素剂量和使用方案在各中心间可能不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Intravenous administration of heparin during endovascular treatment for ischemic stroke may improve outcomes. However, risks and benefits of this adjunctive therapy remain uncertain. We aimed to evaluate periprocedural intravenous heparin use in Dutch stroke intervention centers and to assess its efficacy and safety. Methods- Patients registered between March 2014 and June 2016 in the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke), including all patients treated with endovascular treatment in the Netherlands, were analyzed. The primary outcome was functional outcome (modified Rankin Scale) at 90 days. Secondary outcomes were successful recanalization (extended Thrombolysis in Cerebral Infarction ≥2B), symptomatic intracranial hemorrhage, and mortality at 90 days. We used multilevel regression analysis to evaluate the association of periprocedural intravenous heparin on outcomes, adjusted for center effects and prognostic factors. To account for possible unobserved confounding by indication, we analyzed the effect of center preference to administer intravenous heparin, defined as percentage of patients treated with intravenous heparin in a center, on functional outcome. Results- One thousand four hundred eighty-eight patients from 16 centers were analyzed, of whom 398 (27%) received intravenous heparin (median dose 5000 international units). There was substantial between-center variability in the proportion of patients treated with intravenous heparin (range, 0%-94%). There was no significant difference in functional outcome between patients treated with intravenous heparin and those without (adjusted common odds ratio, 1.17; 95% CI, 0.87-1.56), successful recanalization (adjusted odds ratio, 1.24; 95% CI, 0.89-1.71), symptomatic intracranial hemorrhage (adjusted odds ratio, 1.13; 95% CI, 0.65-1.99), or mortality (adjusted odds ratio, 0.95; 95% CI, 0.66-1.38). Analysis at center level showed that functional outcomes were better in centers with higher percentages of heparin administration (adjusted common odds ratio, 1.07 per 10% more heparin, 95% CI, 1.01-1.13). Conclusions- Substantial between-center variability exists in periprocedural intravenous heparin use during endovascular treatment, but the treatment is safe. Centers using heparin more often had better outcomes. A randomized trial is needed to further study these effects.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. van de Graaf RA, Chalos V, van Es ACGM, et al. Periprocedural Intravenous Heparin During Endovascular Treatment for Ischemic Stroke: Results From the MR CLEAN Registry. Stroke. 2019. PMID: 31860411. doi:10.1161/STROKEAHA.119.025329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。